Thus, this preclinical evidence links myeloid cell TF-PAR2 signaling to TF cytoplasmic tail–dependent NOX2 activation, ERK phosphorylation, and TGF-β1 activation in MI and adverse cardiac remodeling leading to IHF. The gene discussed is TGFB1; the disease is myocardial infarction.